Cancer Research  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 40, 2808-2813, August 1, 1980]
© 1980 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krishnaraj, R.
Right arrow Articles by Kemp, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krishnaraj, R.
Right arrow Articles by Kemp, R. G.

Binding of Monosialoganglioside by Murine Thymus Cells in Vitro1

Rajabather Krishnaraj, Yeheskel A. Saat and Robert G. Kemp2

Department of Biochemistry, University of Health Sciences/The Chicago Medical School, Chicago, Illinois 60612

Binding of tritium-labeled monosialoganglioside (GM1) by intact thymocytes of young AKR/J mice was studied in vitro. The binding was dependent on time, temperature, concentration of cells, and ganglioside, suggesting that the cells possess a finite number of GM1-binding sites. Binding, which could be observed as early as 15 sec, was very rapid, reaching a plateau in about 5 min, followed by a slow and steady increment up to 4 hr of incubation. Cellular binding of GM1 appeared to be tight with very little exchange with exogenous gangliosides. GM1 was almost entirely recovered intact 30 min after it was bound by thymus cells. The structural components of GM1 (galactose, glucose, N-acetylneuraminic acid, mixed ceramides, and lactosylceramide) did not compete with GM1 for cellular binding. The relative specificity of the GM1-binding site was revealed by the lack of competition by lactosylceramide and very weak competition by disialoganglioside and trisialoganglioside that appeared to be due to a GM1 contamination in these preparations. Further characterization of the GM1-thymocyte interaction indicated that it was a Ca2+-dependent process, since chelating agents ethyleneglycolbis(ß-aminoethyl ether)-N,N'-tetraacetic acid and ethylenediaminetetraacetic acid inhibited the binding up to 75 to 80%, and the inhibition by ethyleneglycolbis(ß-aminoethyl ether)-N,N'-tetraacetic acid was reversed by the addition of excess of Ca2+. Also, there appeared to be no overlap of the GM1-binding site with the binding site for concanavalin A. Finally, a comparison of the amount of GM1 bound by leukemic and nonleukemic thymus cells revealed that the tumor cells have a higher capacity to bind GM1 molecules than do normal thymus cells on a per cell basis under several experimental conditions.

1 Supported by USPHS Grant CA 21631 from the National Cancer Institute.

2 To whom requests for reprints should be addressed.

Received 11/14/79. Accepted 5/12/80.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1980 by the American Association for Cancer Research.